Combination Antithrombotic Therapies

被引：93

作者：

Gurbel, Paul A. ^{[1
]}

Tantry, Udaya S. ^{[1
]}

机构：

[1] Sinai Hosp, Sinai Ctr Thrombosis Res, Cardiac Catheterizat Labs, Baltimore, MD 21215 USA

来源：

CIRCULATION | 2010年 / 121卷 / 04期

关键词：

platelets; thrombosis; coronary artery disease; aspirin; thienopyridine; bleeding; PERCUTANEOUS CORONARY INTERVENTION; DUAL ANTIPLATELET THERAPY; ELEVATION MYOCARDIAL-INFARCTION; MAINTENANCE-DOSE CLOPIDOGREL; P2Y(12) RECEPTOR ANTAGONIST; ELUTING STENT IMPLANTATION; TRANSIENT ISCHEMIC ATTACK; HIGH-RISK PATIENTS; PLATELET-AGGREGATION; DOUBLE-BLIND;

D O I：

10.1161/CIRCULATIONAHA.109.853085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：569 / 583

页数：15

共 113 条

[1] Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [J].

Aleil, B ;

Ravanat, C ;

Cazenave, JP ;

Rochoux, G ;

Heitz, A ;

Gachet, C .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :85-92

[2] Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study [J].

Aleil, Boris ;

Jacquemin, Laurent ;

De Poli, Fabien ;

Zaehringer, Michel ;

Collet, Jean-Philippe ;

Montalescot, Gilles ;

Cazenave, Jean-Pierre ;

Dickele, Marie-Claude ;

Monassier, Jean-Pierre ;

Gachet, Christian .

JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (06) :631-638

[3]

[Anonymous], SAFETY TOLERABILITY, DOI DOI 10.1248/bpb.34.1841

[4] Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model [J].

Aoki, M ;

Morishita, R ;

Hayashi, S ;

Jo, N ;

Matsumoto, K ;

Nakamura, T ;

Kaneda, Y ;

Ogihara, T .

DIABETOLOGIA, 2001, 44 (08) :1034-1042

[5]

Aubert RE, 2008, CIRCULATION, V118, pS815

[6] Cardiovascular responses to the isoprostanes iPF2α-III and iPE2-III are mediated via the thromboxane A2 receptor in vivo [J].

Audoly, LP ;

Rocca, B ;

Fabre, JE ;

Koller, BH ;

Thomas, D ;

Loeb, AL ;

Coffman, TM ;

FitzGerald, GA .

CIRCULATION, 2000, 101 (24) :2833-2840

[7]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[8] Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study [J].

Becker, Richard C. ;

Moliterno, David J. ;

Jennings, Lisa K. ;

Pieper, Karen S. ;

Pei, Jinglan ;

Niederman, Alan ;

Ziada, Khaled M. ;

Berman, Gail ;

Strony, John ;

Joseph, Diane ;

Mahaffey, Kenneth W. ;

Van de Werf, Frans ;

Veltri, Enrico ;

Harrington, Robert A. .

LANCET, 2009, 373 (9667) :919-928

[9] Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].

Bertrand, ME ;

Rupprecht, HJ ;

Urban, P ;

Gershlick, AH .

CIRCULATION, 2000, 102 (06) :624-629

[10] Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study [J].

Bertrand, ME ;

Legrand, V ;

Boland, J ;

Fleck, E ;

Bonnier, J ;

Emmanuelson, H ;

Vrolix, M ;

Missault, L ;

Chierchia, S ;

Casaccia, M ;

Niccoli, L ;

Oto, A ;

White, C ;

Webb-Peploe, M ;

Van Belle, E ;

McFadden, EP .

CIRCULATION, 1998, 98 (16) :1597-1603

← 1 2 3 4 5 6 7 8 9 10 →